UAS Technikum Wien collaborates on European Health Data Space
11 August, 2023
In the IDERHA consortium, 33 European partners cooperate to make data and research results on lung cancer more usable for the benefit of patients.
In April, the official go-ahead was given for IDERHA (Integration of Heterogeneous Data and Evidence towards Regulatory and HTA Acceptance), a new Europe-wide consortium of 33 public and private institutions, including UAS Technikum Wien. The aim of the project is to make the flood of data in the health sector accessible and use it in a meaningful way in order to give lung cancer patients in particular new opportunities for individual therapies and healing in the future.
Among other things, the project will create the first pan-European Health Data Space. In addition, recommendations will be made to politicians and public authorities on how heterogeneous data and research results can be successfully used in the healthcare system for the benefit of patients.
Secure Health Data Spaces for Europe
European Health Data Spaces are to be established on the proposal of the European Commission. These European Health Data Spaces consist of rules, common standards and procedures, infrastructures and a governance framework. The goals:
Support citizens in taking control of their own health data.
Support the use of health data for better healthcare, research, innovation and policy.
To enable the EU to fully realize the potential of secure exchange, use and reuse of health data.
Technikum Wien contributes expertise
The interdisciplinary project team from the faculties of Life Science Engineering and Computer Science is contributing its expertise in semantic interoperability, IT standards, APIs, data management and training to IDERHA, and is looking forward to working with high-level project partners from across Europe. IDERHA is led by the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP and Johnson & Johnson Medical GmbH. The consortium brings together 33 academic, clinical, medical device, pharmaceutical, IT, patient and public sector organizations. The project runs from April 2023 to March 31, 2028 and is led at FHTW by Lukas Rohatsch.
About the IHI
The IHI (Innovative Health Initiative) aims to translate health research and innovation into real benefits for patients and society. It aims to ensure that Europe remains a leader in interdisciplinary, sustainable and patient-centered health research. Increasingly, health research and care involve different sectors; by supporting projects that bring these sectors together, the IHI will pave the way for a more integrated approach to healthcare that encompasses prevention, diagnosis, treatment and disease management.
The IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical device, biotechnology, digital health and vaccines sectors, namely COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. The IHI’s total budget is €2.4 billion. Half of this comes from Horizon Europe, the EU’s research and innovation program. IHI industry partners have pledged €1 billion to the IHI, and another €200 million may be provided by other organizations that decide to become contributing partners.
The IHI builds on the successes of the Innovative Medicines Initiative (IMI), and the IHI Programs Office manages the IMI project portfolio.
Funding and Disclaimer
This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under Grant Agreement No. 101112135. JU is supported by the European Union’s Horizon Europe research and innovation program and the life sciences industry, represented by COCIR, EFPIA / Vaccines Europe, EuropaBio, and MedTech Europe.
IDERHA is funded by the European Union, private members and partners of IHI JU. However, the views and opinions expressed are solely those of the authors and do not necessarily reflect those of the above parties. None of the above parties can be held responsible for them.